دورية أكاديمية
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
| العنوان: | Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib |
|---|---|
| المؤلفون: | Rimassa, Lorenza, Abbadessa, Giovanni, Personeni, Nicola, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Salvagni, Stefania, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Trojan, Jörg, De Toni, Enrico N, Weiss, Alan, Miles, Steven, Gasbarrini, Antonio, Lencioni, Monica, Lamar, Maria E, Wang, Yunxia, Shuster, Dale, Schwartz, Brian E, Santoro, Armando |
| المصدر: | ONCOTARGET ; ISSN: 1949-2553 |
| سنة النشر: | 2016 |
| المجموعة: | Ghent University Academic Bibliography |
| مصطلحات موضوعية: | Medicine and Health Sciences, sorafenib, DISPLAYS CYTOTOXIC ACTIVITY, AFP, HGF, MET, HCC, C-MET, ARQ 197, ADULT PATIENTS, TYROSINE KINASE, SOLID TUMORS, DOUBLE-BLIND, LUNG-CANCER, BIND MET |
| الوصف: | ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC. Aim of this research was to study the prognostic and predictive value of tumor (MET, the receptor tyrosine kinase encoded by the homonymous MNNG-HOS transforming gene) and circulating (MET, hepatocyte growth factor [HGF], alpha-fetoprotein [AFP], vascular endothelial growth factor [VEGF]) biomarkers in second-line HCC. Tumor MET-High status was centrally assessed by immunohistochemistry. Circulating biomarkers were centrally analyzed on serum samples collected at baseline and every 4-8 weeks, using medians as cut-off to determine High/Low status. Tumor MET, tested in 77 patients, was more frequently High after (82%) versus before (40%) sorafenib. A significant interaction (p = 0.04) between tivantinib and baseline tumor MET in terms of survival was observed. Baseline circulating MET and HGF (102 patients) High status correlated with shorter survival (HR 0.61, p = 0.03, and HR 0.60, p = 0.02, respectively), while the association between AFP (104 patients) or VEGF (103 patients) status and survival was non-significant. Conclusions: Tumor MET levels were higher in patients treated with sorafenib. Circulating biomarkers such as MET and HGF may be prognostic in second-line HCC. These results need to be confirmed in larger randomized clinical trials. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://biblio.ugent.be/publication/8200522Test; http://hdl.handle.net/1854/LU-8200522Test; http://dx.doi.org/10.18632/oncotarget.11621Test; https://biblio.ugent.be/publication/8200522/file/8200548Test |
| DOI: | 10.18632/oncotarget.11621 |
| الإتاحة: | https://doi.org/10.18632/oncotarget.11621Test https://biblio.ugent.be/publication/8200522Test http://hdl.handle.net/1854/LU-8200522Test https://biblio.ugent.be/publication/8200522/file/8200548Test |
| حقوق: | No license (in copyright) ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F4B27E09 |
| قاعدة البيانات: | BASE |
| DOI: | 10.18632/oncotarget.11621 |
|---|